• Home
  • Cardiovascular
  • Cardiovascular Safety in Drug Development and Therapeutic by J. Rick Turner, Dilip R. Karnad, Snehal Kothari

Cardiovascular Safety in Drug Development and Therapeutic by J. Rick Turner, Dilip R. Karnad, Snehal Kothari

By J. Rick Turner, Dilip R. Karnad, Snehal Kothari

At a time while the sector of cardiac protection goes via very important adjustments, this detailed publication presents the reason for, and state of the art reasons of, new regulatory landscapes that may most probably govern cardiac safeguard tests globally for the foreseeable future.  Exposure-response modeling is already being accredited by means of regulatory organizations in lieu of the conventional Thorough QT/QTc examine, and the excellent in vitro Proarrhythmia Assay initiative is easily less than way.

Developments within the box of cardiovascular security also are defined and mentioned within the book.  those comprise the quest for extra effective how one can exonerate new medications for variety 2 diabetes from an unacceptable cardiovascular legal responsibility, how top to handle off-target blood strain raises brought on by means of noncardiovascular medicinal drugs, and the continuing evolution of the self-discipline of Cardio-oncology.

Show description

Read or Download Cardiovascular Safety in Drug Development and Therapeutic Use: New Methodologies and Evolving Regulatory Landscapes PDF

Best cardiovascular books

Atherosclerosis: Experimental Methods and Protocols

Kid's clinic study starting place, Cincinnati, OH. allows biomedical researchers to pick these optimized recommendations that could be used to review the improvement, development, and therapy of atherosclerotic lesions. define layout.

ABC of Hypertension

Hypertension is a standard power scientific challenge encountered in fundamental care, but it's quite often below clinically determined. ABC of high blood pressure is a protracted validated, useful consultant to the research, remedy and administration of hypertensive sufferers. This 6th edition:Provides sensible counsel on dimension of blood strain and the research and administration of hypertensive patientsExplains new advancements in size and automatic dimension of blood strain andUpdates insurance on therapy of the aged and explains of the consequences of contemporary trialsIncorporates present British high blood pressure Society and great guidance

Molecular and Multimodality Imaging in Cardiovascular Disease

This e-book presents the main updated insurance of the mixed use of imaging modalities as a way to gather vital useful and morphological details on heart problems and improve affliction detection. the new advancements in PET/MRI, cardiac CT, PET/CT and SPECT/CT and their influence on medical perform are defined and precise cognizance is usually dedicated to imaging parameters and protocols to be used in perform and study.

Additional resources for Cardiovascular Safety in Drug Development and Therapeutic Use: New Methodologies and Evolving Regulatory Landscapes

Sample text

Historically, populations that were easily and conveniently accessed by researchers, such as prison inmates, nursing home residents, and people with poor access to general health care, have been included in clinical trials when they should not have been. Vulnerable populations in which individuals may find it difficult to refuse participation in a study should not be deliberately chosen for participation in clinical trials when non-vulnerable populations would also be appropriate. The benefits of participation, such as access to potentially lifesaving new therapies, should be available to all, including those not historically well represented in the clinical research enterprise, such as women, children, and members of ethnic minorities.

Crit Care Clin 31:675–684 Karpa KD, Felix TM, Lewis PR (2015) Adverse effects of common drugs: children and adolescents. FP Essent 436:17–22 Karpa KD, Lewis PR, Felix TM (2015) Adverse effects of common drugs: general concepts. FP Essent 436:11–16 Kim SH, Naisbitt DJ (2016) Update on advances in research on idiosyncratic drug-induced liver injury. Allergy Asthma Immunol Res 8:3–11 Kitai Y, Matsubara T, Yanagita M (2015) Onco-nephrology: current concepts and future perspectives. Jpn J Clin Oncol 4:617–628 Ku LC, Smith PB (2015) Dosing in neonates: special considerations in physiology and trial design.

Oncotarget 6:39538–39549 Paparella M, Martina V, Rizzo MA, Gallieni M (2015) What every doctor should know about drug safety in patients with chronic kidney disease. Contrib Nephrol 184:24–50 Pazhayattil GS, Shirali AC (2014) Drug-induced impairment of renal function. Int J Nephrol Renovasc Dis 7:457–468 Perazella MA, Izzedine H (2015) New drug toxicities in the onco-nephrology world. Kidney Int 87:909–917 Pirmohamed M, Ostrov DA, Park BK (2015) New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity.

Download PDF sample

Rated 4.96 of 5 – based on 25 votes